ERAS.US Erasca Inc

Healthcare Biotechnology USA Stocks
15.66 USD
Close of Nov 14, 2026
2.52 24.28
Market cap
USD 5.48B
P/E
-
P/B
15.26x
ROE
-40.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ERAS.US undervalued?

Graham number

The Graham number of Erasca Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Erasca Inc fundamental analysis

No fundamental analysis for Erasca Inc yet.

Erasca Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) f…

Full company profile